Sizing battery energy storage systems: using multi-objective optimisation to overcome the investment scale problem of annual worth

The financial objective, when sizing a Battery Energy Storage System (BESS) for installation in a microgrid, is to maximise the difference between discounted BESS benefits and discounted BESS costs. This may be described as maximising Annual Worth (AW). However, one drawback of sizing microgrid BESS using AW is that the scale of investment is not taken into consideration. This can lead to unrealistic BESS sizes. This paper presents two multi-objective optimisation (MOO) models to account for the scale of investment required in sizing BESS. The first model, Paired Comparison, utilises two objective functions: Daily Worth (DW), which maximises daily benefit cost differences a BESS installation provides a microgrid; and Daily Cost (DC), which minimises the daily cost of a BESS installation. The second model, called Rating Method, uses the objective functions DW and Daily Benefit-Cost Ratio (DBCR), the latter of which maximises the relative measure of BESS benefit and BESS cost. Both models are solved for a test microgrid system under three different scenarios using Compromise Programming (CP). For system designers who rank objective functions by importance, the Rating Method is the appropriate approach, whereas system designers who rank objective functions by absolute values should use Paired Comparison

Kinetics of toluene degradation by toluene-oxidizing bacteria as a function of oxygen concentration, and the effect of nitrate

The kinetics of toluene degradation as a function of oxygen concentration were compared for six strains of toluene-oxidizing bacteria using initial rate assays. The effect of nitrate was also examined. Rates of degradation and the relative effect of oxygen on the degradation rate were correlated with the pathway for toluene oxidation. Strains which synthesize toluene dioxygenases, Pseudomonas putida F1, P. fluorescens CFS215, and Pseudomonas sp. strain W31, degraded toluene at significantly higher rates (151–166 nmol/mg per min) than strains synthesizing toluene monooxygenases, Burkholderia cepacia G4 (23 nmol/mg per min) and B. pickettii PKO1 (14 nmol/mg per min), or a methylmonooxygenase, P. putida PaW1 (12 nmol/mg per min). Rates declined 30–48% for the dioxygenase strains and 25% for PaW1 as the oxygen concentration was decreased from 240 to 50 ΜM, but declined less than 10% for G4 and PKO1. Nitrate enhanced toluene degradation by the denitrifying strains PKO1 and W31 at oxygen concentrations below 30 ΜM, but had no significant effect on any of the other strains. Biphasic kinetics were observed for all of the strains, with double-reciprocal plots of the data exhibiting an inflection point at a ‘critical oxygen concentration’ between 20 and 30 ΜM. Below this concentration, the rate of toluene degradation was inhibited to a greater extent than predicted by the kinetic data for higher oxygen concentrations. For the denitrifying strains PKO1 and W31, however, monophasic kinetics were observed when nitrate was provided as an alternative electron acceptor. These observations suggest that biphasic kinetics result when rates of toluene degradation are limited by the availability of electron acceptor at the critical oxygen concentration, and that this limitation is overcome by denitrifying strains able to respire nitrate. Taken together, our findings suggest that the synthesis of monooxygenases and the ability to denitrify represent independent adaptations for toluene utilization in low oxygen environments. Moreover, these data support the use of nitrate in mixed electron acceptor strategies for the bioremediation of contaminated aquifers, as well as the targeted use of monooxygenase and dioxygenase strains in settings in which their physiological traits can be best exploited.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/74870/1/j.1574-6941.1997.tb00387.x.pd

The 74MHz System on the Very Large Array

The Naval Research Laboratory and the National Radio Astronomy Observatory completed implementation of a low frequency capability on the VLA at 73.8 MHz in 1998. This frequency band offers unprecedented sensitivity (~25 mJy/beam) and resolution (~25 arcsec) for low-frequency observations. We review the hardware, the calibration and imaging strategies, comparing them to those at higher frequencies, including aspects of interference excision and wide-field imaging. Ionospheric phase fluctuations pose the major difficulty in calibrating the array. Over restricted fields of view or at times of extremely quiescent ionospheric ``weather'', an angle-invariant calibration strategy can be used. In this approach a single phase correction is devised for each antenna, typically via self-calibration. Over larger fields of view or at times of more normal ionospheric ``weather'' when the ionospheric isoplanatic patch size is smaller than the field of view, we adopt a field-based strategy in which the phase correction depends upon location within the field of view. This second calibration strategy was implemented by modeling the ionosphere above the array using Zernike polynomials. Images of 3C sources of moderate strength are provided as examples of routine, angle-invariant calibration and imaging. Flux density measurements indicate that the 74 MHz flux scale at the VLA is stable to a few percent, and tied to the Baars et al. value of Cygnus A at the 5 percent level. We also present an example of a wide-field image, devoid of bright objects and containing hundreds of weaker sources, constructed from the field-based calibration. We close with a summary of lessons the 74 MHz system offers as a model for new and developing low-frequency telescopes. (Abridged)Comment: 73 pages, 46 jpeg figures, to appear in ApJ

A Wide Field, Low Frequency Radio Image of the Field of M31: II. -- Source Classification and Discussion

We have previously presented the results of a 325 MHz radio survey of M31, conducted with the A-configuration of the Very Large Array. In this survey, a total of 405 radio sources between <6" and 170" in extent were mapped with a resolution of 6" and a sensitivity of ~0.6 mJy/beam. Here, we compare the resultant source list and image with other radio, IR, optical, X-ray observations and catalogs of the region. Through this, we were able to identify five supernova remnant (SNR) candidates and three pulsar wind nebula (PWN) candidates in M31, as well as three Milky Way radio stars, a possible Milky Way Planetary Nebula, and a bevy of interesting extragalactic objects: a BL Lac, a Giant Radio Galaxy, a galaxy merger, and several high-z radio galaxy candidates. In addition, a large number of compact (<6") extremely steep spectrum sources ($\alpha \leq -1.6; S_{\nu} \propto \nu^{\alpha}$) were detected whose nature is unknown.Comment: 30 pages, 23 tables, + 18 figures. Low-resolution figures are available here in .jpg form. ApJS accepted, to be published in August 2005, v159 2 issu

Role of the Transcriptional Corepressor Bcor in Embryonic Stem Cell Differentiation and Early Embryonic Development

Bcor (BCL6 corepressor) is a widely expressed gene that is mutated in patients with X-linked Oculofaciocardiodental (OFCD) syndrome. BCOR regulates gene expression in association with a complex of proteins capable of epigenetic modification of chromatin. These include Polycomb group (PcG) proteins, Skp-Cullin-F-box (SCF) ubiquitin ligase components and a Jumonji C (Jmjc) domain containing histone demethylase. To model OFCD in mice and dissect the role of Bcor in development we have characterized two loss of function Bcor alleles. We find that Bcor loss of function results in a strong parent-of-origin effect, most likely indicating a requirement for Bcor in extraembryonic development. Using Bcor loss of function embryonic stem (ES) cells and in vitro differentiation assays, we demonstrate that Bcor plays a role in the regulation of gene expression very early in the differentiation of ES cells into ectoderm, mesoderm and downstream hematopoietic lineages. Normal expression of affected genes (Oct3/4, Nanog, Fgf5, Bmp4, Brachyury and Flk1) is restored upon re-expression of Bcor. Consistent with these ES cell results, chimeric animals generated with the same loss of function Bcor alleles show a low contribution to B and T cells and erythrocytes and have kinked and shortened tails, consistent with reduced Brachyury expression. Together these results suggest that Bcor plays a role in differentiation of multiple tissue lineages during early embryonic development

Fibronectin Unfolding Revisited: Modeling Cell Traction-Mediated Unfolding of the Tenth Type-III Repeat

Fibronectin polymerization is essential for the development and repair of the extracellular matrix. Consequently, deciphering the mechanism of fibronectin fibril formation is of immense interest. Fibronectin fibrillogenesis is driven by cell-traction forces that mechanically unfold particular modules within fibronectin. Previously, mechanical unfolding of fibronectin has been modeled by applying tensile forces at the N- and C-termini of fibronectin domains; however, physiological loading is likely focused on the solvent-exposed RGD loop in the 10th type-III repeat of fibronectin (10FNIII), which mediates binding to cell-surface integrin receptors. In this work we used steered molecular dynamics to study the mechanical unfolding of 10FNIII under tensile force applied at this RGD site. We demonstrate that mechanically unfolding 10FNIII by pulling at the RGD site requires less work than unfolding by pulling at the N- and C- termini. Moreover, pulling at the N- and C-termini leads to 10FNIII unfolding along several pathways while pulling on the RGD site leads to a single exclusive unfolding pathway that includes a partially unfolded intermediate with exposed hydrophobic N-terminal β-strands – residues that may facilitate fibronectin self-association. Additional mechanical unfolding triggers an essential arginine residue, which is required for high affinity binding to integrins, to move to a position far from the integrin binding site. This cell traction-induced conformational change may promote cell detachment after important partially unfolded kinetic intermediates are formed. These data suggest a novel mechanism that explains how cell-mediated forces promote fibronectin fibrillogenesis and how cell surface integrins detach from newly forming fibrils. This process enables cells to bind and unfold additional fibronectin modules – a method that propagates matrix assembly

The ASKAP-EMU Early Science Project: Radio Continuum Survey of the Small Magellanic Cloud

We present two new radio continuum images from the Australian Square Kilometre Array Pathfinder (ASKAP) survey in the direction of the Small Magellanic Cloud (SMC). These images are part of the Evolutionary Map of the Universe (EMU) Early Science Project (ESP) survey of the Small and Large Magellanic Clouds. The two new source lists produced from these images contain radio continuum sources observed at 960 MHz (4489 sources) and 1320 MHz (5954 sources) with a bandwidth of 192 MHz and beam sizes of 30.0”×30.0” and 16.3”×15.1”, respectively. The median Root Mean Squared (RMS) noise values are 186 μJy beam−1 (960 MHz) and 165 μJy beam−1 (1320 MHz). To create point source catalogues, we use these two source lists, together with the previously published Molonglo Observatory Synthesis Telescope (MOST) and the Australia Telescope Compact Array (ATCA) point source catalogues to estimate spectral indices for the whole population of radio point sources found in the survey region. Combining our ASKAP catalogues with these radio continuum surveys, we found 7736 point-like sources in common over an area of 30 deg2. In addition, we report the detection of two new, low surface brightness supernova remnant candidates in the SMC. The high sensitivity of the new ASKAP ESP survey also enabled us to detect the bright end of the SMC planetary nebula sample, with 22 out of 102 optically known planetary nebulae showing point-like radio continuum emission. Lastly, we present several morphologically interesting background radio galaxies

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial

Abstract: Background: Parkinson’s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals’ needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. Methods/design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016